Fulgent Genetics, Inc. (FRA:7F0)

Market Cap	681.70M +35.6%
Revenue (ttm)	268.94M +13.6%
Net Income	-36.63M
EPS	-1.20
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	35
Open	22.60
Previous Close	23.20
Day's Range	22.60 - 22.60
52-Week Range	14.50 - 26.60
Beta	n/a
RSI	35.72
Earnings Date	Feb 27, 2026

About Fulgent Genetics

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he...

• Industry: Medical Laboratories
• Founded: 2011
• Employees: 1,313
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 7F0

Financial Performance

In 2024, Fulgent Genetics's revenue was $283.47 million, a decrease of -1.99% compared to the previous year's $289.21 million. Losses were -$42.71 million, -74.55% less than in 2023.

Financial numbers in USD